{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:42:01Z","timestamp":1789684921784,"version":"4.0.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze and evaluate the impact of SGLT2 inhibitors on the renal outcomes of patients with type 2 diabetes mellitus and chronic kidney disease, and to provide evidence-based basis for clinical rational treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relevant literatures on the impact of SGLT2 inhibitors on the renal outcomes of patients with type 2 diabetes mellitus and chronic kidney disease published in domestic and foreign databases were retrieved and collected. The time limit was from the establishment of each database to November 2025. After screening, the quality of the research literature was evaluated using the Cochrane library. Literature management was conducted using NoteExpress 3.2, and data collection and extraction were carried out using Excel 2003. Statistical analysis was performed using RevMan 5.4.1 software. Based on the size of the Q test (P value), it was determined whether there was heterogeneity in the studies, and then the fixed or random effect model was used to calculate the combined effect OR value, and a forest plot was drawn. Then, the publication bias was evaluated by drawing a funnel plot.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 10 studies that met the inclusion criteria were finally included. The meta-analysis results showed that compared with the control group, the eGFR and CrCI levels of patients treated with 5 mg dapagliflozin showed a more significant decline, renal-related adverse events (OR = 0.91, 95% CI: 0.84 to 0.99, P = 0.04), and the occurrence of doubling of serum creatinine, end-stage renal disease, and renal death events (OR = 0.68, 95% CI: 0.60 to 0.78, P &amp;lt; 0.00001). However, there was no statistically significant difference in acute kidney injury or failure between the two groups. Sensitivity analysis suggested that the results of this study were stable and reliable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2 inhibitors can cause a short-term decline in eGFR and CrCl, and significantly reduce the risk of renal composite endpoint events. This indicates that their early hemodynamic effects are predictable physiological changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261294499<\/jats:ext-link>\n                      , identifier CRD420261294499.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1785822","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:31:04Z","timestamp":1777005064000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes and chronic kidney disease: systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Ya","family":"Su","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Shaanxi Provincial People\u2019s Hospital","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shaanxi Provincial People\u2019s Hospital","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shaanxi Provincial People\u2019s Hospital","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.03.020","article-title":"Prevalence of chronic kidney disease and associated factors in Chinese individuals with type 2 diabetes: Cross-sectional study","volume":"30","author":"Guo","year":"2016","journal-title":"J Diabetes Complications"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF Diabetes Atlas: globalestimates of the prevalence of diabetes for 201l and 2030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.2007.s94","article-title":"Diabetic nephropathy","volume":"26","author":"Molitch","year":"2003","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases:pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2113","article-title":"Osteocalcin and risks of incident diabetes and diabetic kidney disease: a 4.6-year prospective cohort study","volume":"45","author":"Ye","year":"2022","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1602469","article-title":"Trends in chronic kidney disease in China","volume":"375","author":"Zhang","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"280\u2212289","DOI":"10.1001\/jama.2016.19720","article-title":"Association between diabetes and cause\u2212specific mortality in rural and urban areas of China","volume":"317","author":"Bragg","year":"2017","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2169\/internalmedicine.56.7196","article-title":"Sodium-glucose co-transporter 2 inhibitors reduce theAbdominal visceral fat area and may influence the renal function in patients with type 2Diabetes","volume":"56","author":"Tosaki","year":"2017","journal-title":"Intem Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"NEngl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double -blind,placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e002484","DOI":"10.1136\/bmjdrc-2021-002484","article-title":"Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial","volume":"9","author":"Dagogo-Jack","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12403","article-title":"A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study","volume":"17","author":"Kashiwagi","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx350","article-title":"Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease","volume":"33","author":"Dekkers","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/jdi.13624","article-title":"Renal, cardiovascular and safety outcomes of canagliflozin in patients with type\u20092 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial","volume":"13","author":"Wada","year":"2022","journal-title":"J Diabetes Investig"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13888","article-title":"Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type\u20092 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase\u2009III study in Japan","volume":"13","author":"Wada","year":"2022","journal-title":"J Diabetes Investig"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"m997","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study","volume":"369","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: a cross-sectional survey","volume":"379","author":"Zhang","year":"2012","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz174","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"34","author":"Jager","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.39","article-title":"Relation between kidney function, proteinuria, and adverse outcomes","volume":"303","author":"Hemmelgarn","year":"2010","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose cotransporter inhibitors and oxidative stress: An update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J Cell Physiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv093","article-title":"Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents","volume":"31","author":"Gnudi","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051083","article-title":"SGLT2 inhibitors as a therapeutic option for diabetic nephropathy","volume":"18","author":"Kawanami","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74297","article-title":"Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition","volume":"124","author":"Cefalu","year":"2014","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00551.2017","article-title":"SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism","volume":"314","author":"Layton","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203869","article-title":"Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats","volume":"345","author":"Kojima","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-02080-1","article-title":"Cardiovascular and renal outcomes of sodium-glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes post-PCI: a meta-analysis of 14,511 patients","volume":"18","author":"Badran","year":"2026","journal-title":"Diabetol Metab Syndr"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1785822\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:31:24Z","timestamp":1777005084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1785822\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":46,"alternative-id":["10.3389\/fendo.2026.1785822"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1785822","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"1785822"}}